NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$44.62

+0.47 (+1.06%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $44.01
▼
$46.57
50-Day Range: $36.06
▼
$69.85
52-Week Range: $20.63
▼
$71.98

Volume: 1.09 million shs
Average Volume: 1.10 million shs
Market Capitalization: $1.74 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $108.56

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 146.5% Upside
$110.00 Price Target
Short Interest: Healthy
17.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 0.75
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.35) to ($2.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

309th out of 1,093 stocks

Pharmaceutical Preparations Industry

139th out of 547 stocks

3.4

Analyst's Opinion

Consensus Rating
Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $110.00, Axsome Therapeutics has a forecasted upside of 146.5% from its current price of $44.62.
Amount of Analyst Coverage
Axsome Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
17.68% of the float of Axsome Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Axsome Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Axsome Therapeutics has recently decreased by 3.72%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Axsome Therapeutics does not currently pay a dividend.
Dividend Growth
Axsome Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Axsome Therapeutics has received a 68.62% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.
Environmental Sustainability
The Environmental Impact score for Axsome Therapeutics is -1.12.

2.1

News and Social Media Coverage

News Sentiment
Axsome Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Axsome Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 40 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -68% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.00% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.96% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.35) to ($2.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axsome Therapeutics is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axsome Therapeutics is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axsome Therapeutics has a P/B Ratio of 108.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

September 30, 2022 | finance.yahoo.com

Axsome Therapeutics (AXSM) Gains As Market Dips: What You Should Know

September 30, 2022 | markets.businessinsider.com

8 Analysts Have This to Say About Axsome Therapeutics

September 29, 2022 | marketwatch.com

Axsome to Refile AXS-07 Migraine Application in 3Q23 >AXSM

September 29, 2022 | finance.yahoo.com

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

September 26, 2022 | finance.yahoo.com

2 No-Brainer Biotech Stocks to Buy Right Now

September 23, 2022 | finance.yahoo.com

If You Invested $10,000 in Axsome Therapeutics 5 Years Ago, This Is How Much You Would Have Today

September 23, 2022 | americanbankingnews.com

Axsome Therapeutics (NASDAQ:AXSM) Trading Down 5%

September 21, 2022 | nasdaq.com

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) institutional investors lost 4.6% over the past week but have profited from longer-term gains

September 21, 2022 | finance.yahoo.com

Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

September 20, 2022 | 247wallst.com

These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022

September 17, 2022 | finance.yahoo.com

Is It Too Late to Buy Axsome Therapeutics Stock?

September 15, 2022 | finance.yahoo.com

3 Top Healthcare Stocks Defying the Bear Market

September 9, 2022 | finance.yahoo.com

Wall Street Analysts are Recommending These 10 Stocks in September

September 8, 2022 | finance.yahoo.com

Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report?

September 8, 2022 | finance.yahoo.com

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

September 7, 2022 | finance.yahoo.com

Mizuho Bolsters Price Target By 55% On This Migraine Stock

September 7, 2022 | finance.yahoo.com

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

September 1, 2022 | msn.com

Axsome Therapeutics Commences Late-Stage Migraine Study

September 1, 2022 | finance.yahoo.com

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

August 30, 2022 | markets.businessinsider.com

Analyst Ratings for Axsome Therapeutics

August 30, 2022 | markets.businessinsider.com

Expert Ratings for Axsome Therapeutics

August 29, 2022 | msn.com

$1000 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth This Much Today

August 28, 2022 | finance.yahoo.com

3 Healthcare Stocks That Are Beating the Market

August 25, 2022 | finance.yahoo.com

Why Axsome Therapeutics Stock Jumped This Week

August 24, 2022 | msn.com

Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings: 8/09/2022
Today: 10/01/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AXSM
CUSIP: N/A
CIK: 1579428
Web: axsome.com
Phone: (212) 332-3241
Fax: 212-320-0245
Employees: 108
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $110.00
High Stock Price Forecast: $210.00
Low Stock Price Forecast: $54.00
Forecasted Upside/Downside: +143.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-130,400,000.00
Net Margins: N/A
Pretax Margin: -1,699.89%
Return on Equity: -679.57%
Return on Assets: -126.65%

Debt

Debt-to-Equity Ratio: 6.15
Current Ratio: 2.44
Quick Ratio: 2.20

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 108.83

Miscellaneous

Outstanding Shares: 38,910,000
Free Float: 28,796,000
Market Cap: $1.74 billion
Optionable: Optionable
Beta: 1.68

Key Executives

Dr. Herriot Tabuteau M.D. (Age 54)
Founder, Chairman, CEO & Pres
Comp: $1.06M

Mr. Nick Pizzie CPA (Age 47)
M.B.A., Chief Financial Officer
Comp: $553.97k

Mr. Mark L. Jacobson (Age 39)
COO & Sec.
Comp: $554.72k

Mr. Hunter Murdock Esq.
Exec. VP of Legal & Compliance

Dr. Amanda Jones Pharm.D. (Age 39)
Sr. VP of Clinical Devel.

Ms. Lori Englebert M.B.A. (Age 44)
Exec. VP of Commercial & Bus. Devel.

Mr. Kevin Laliberte Pharm.D. (Age 44)
Exec. VP of Product Strategy

Joseph Debrah-Afful CPA
M.B.A., Director of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.
What is Axsome Therapeutics' stock price forecast for 2022?: 8 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $54.00 to $210.00. On average, they anticipate the company's share price to reach $110.00 in the next twelve months. This suggests a possible upside of 146.5% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.
How have AXSM shares performed in 2022?: Axsome Therapeutics' stock was trading at $37.78 at the beginning of the year. Since then, AXSM shares have increased by 18.1% and is now trading at $44.62.
View the best growth stocks for 2022 here.
When is Axsome Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AXSM earnings forecast.
How were Axsome Therapeutics' earnings last quarter?: Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.13. The firm earned $8.82 million during the quarter, compared to analysts' expectations of $9.59 million. During the same period in the previous year, the firm earned ($0.86) EPS.
What other stocks do shareholders of Axsome Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?: (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
What is Axsome Therapeutics' stock symbol?: Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
How do I buy shares of Axsome Therapeutics?: Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Axsome Therapeutics' stock price today?: One share of AXSM stock can currently be purchased for approximately $44.62.
How much money does Axsome Therapeutics make?: Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $1.74 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.
How many employees does Axsome Therapeutics have?: The company employs 108 workers across the globe.
How can I contact Axsome Therapeutics?: Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Axsome Therapeutics - AXSM Stock Forecast, Price & News

Axsome Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows